Rapt Therapeutics, Inc. (RAPT)

NASDAQ: RAPT · IEX Real-Time Price · USD
24.06
+0.19 (0.80%)
At close: Sep 30, 2022 4:00 PM
22.86
-1.20 (-4.99%)
After-hours: Sep 30, 2022 7:50 PM EDT
0.80%
Market Cap 713.54M
Revenue (ttm) 3.25M
Net Income (ttm) -76.23M
Shares Out 29.66M
EPS (ttm) -2.56
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 603,275
Open 23.87
Previous Close 23.87
Day's Range 23.28 - 25.14
52-Week Range 9.86 - 40.74
Beta 0.44
Analysts Buy
Price Target 46.92 (+95.0%)
Earnings Date Nov 8, 2022

About RAPT

RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. The company's lead oncology drug candidate is FLX475, an oral small molecule CCR4 antagonist that is in the Phase 1/2 clini... [Read more...]

Industry Biotechnology
IPO Date Oct 31, 2019
CEO Brian Wong
Employees 88
Stock Exchange NASDAQ
Ticker Symbol RAPT
Full Company Profile

Financial Performance

In 2021, RAPT's revenue was $3.81 million, a decrease of -24.38% compared to the previous year's $5.04 million. Losses were -$69.20 million, 30.8% more than in 2020.

Financial Statements

Analyst Forecast

According to 13 analysts, the average rating for RAPT stock is "Buy." The 12-month stock price forecast is 46.92, which is an increase of 95.01% from the latest price.

Price Target
$46.92
(95.01% upside)
Analyst Consensus: Buy
Stock Forecasts

News

RAPT Therapeutics Strengthens Leadership Team with Two New Key Hires

SOUTH SAN FRANCISCO, Calif., Sept. 28, 2022 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing an...

4 days ago - GlobeNewsWire

Rapt Therapeutics (RAPT) Upgraded to Buy: Here's What You Should Know

Rapt Therapeutics (RAPT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

1 week ago - Zacks Investment Research

Here's Why Rapt Therapeutics (RAPT) Looks Ripe for Bottom Fishing

After losing some value lately, a hammer chart pattern has been formed for Rapt Therapeutics (RAPT), indicating that the stock has found support. This, combined with an upward trend in earnings estimate...

1 week ago - Zacks Investment Research

How Much Upside is Left in Rapt Therapeutics (RAPT)? Wall Street Analysts Think 74%

The average of price targets set by Wall Street analysts indicates a potential upside of 73.7% in Rapt Therapeutics (RAPT). While the effectiveness of this highly sought-after metric is questionable, th...

1 month ago - Zacks Investment Research

RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in September

SOUTH SAN FRANCISCO, Calif., Aug. 31, 2022 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and...

1 month ago - GlobeNewsWire

Can Rapt Therapeutics (RAPT) Climb 59% to Reach the Level Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 58.9% in Rapt Therapeutics (RAPT). While the effectiveness of this highly sought-after metric is questionable, th...

1 month ago - Zacks Investment Research

Rapt Therapeutics (RAPT) Reports Q2 Loss, Tops Revenue Estimates

Rapt Therapeutics (RAPT) delivered earnings and revenue surprises of 17.33% and 121.50%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

RAPT Therapeutics Reports Second Quarter 2022 Financial Results

Company maintains strong cash position of $207.3 million Company maintains strong cash position of $207.3 million

1 month ago - GlobeNewsWire

This Mid-Cap Firm Can Potentially Offer Biggest Oral Drug In Atopic Dermatitis, Cantor Thinks So

Cantor assumes coverage of RAPT Therapeutics Inc (NASDAQ: RAPT) with an Overweight rating and a price target of $44 (vs. $58 previously).

4 months ago - Benzinga

RAPT Therapeutics Announces Private Placement Financing of $50 Million

SOUTH SAN FRANCISCO, Calif., May 25, 2022 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and ...

4 months ago - GlobeNewsWire

RAPT Therapeutics Announces Initiation of Phase 2b Trial of RPT193 in Patients with Moderate-to-Severe Atopic Dermatitis

SOUTH SAN FRANCISCO, Calif., May 23, 2022 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and ...

4 months ago - GlobeNewsWire

Rapt Therapeutics (RAPT) Reports Q1 Loss, Tops Revenue Estimates

Rapt Therapeutics (RAPT) delivered earnings and revenue surprises of -4.55% and 60.25%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

RAPT Therapeutics Reports First Quarter 2022 Financial Results

Company maintains strong cash position of $173.0 million Company maintains strong cash position of $173.0 million

4 months ago - GlobeNewsWire

RAPT Therapeutics Expands Leadership Team with Multiple Key Hires

SOUTH SAN FRANCISCO, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and ...

4 months ago - GlobeNewsWire

RAPT Therapeutics Announces Biomarker Data from Phase 1b Trial of RPT193 Consistent with Disease Modification in Atop...

Significant improvement in atopic dermatitis gene signatures in patients treated with RPT193 reported in late-breaking presentation at the American Academy of Dermatology Annual Meeting Significant impr...

6 months ago - GlobeNewsWire

RAPT Therapeutics Reports Fourth Quarter and Year End 2021 Financial Results

Company maintains strong cash position of $189.7 million Company maintains strong cash position of $189.7 million

6 months ago - GlobeNewsWire

RAPT Therapeutics to Participate in the 11th Annual SVB Leerink Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Feb. 09, 2022 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and...

7 months ago - GlobeNewsWire

RAPT Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and...

8 months ago - GlobeNewsWire

Rapt Therapeutics (RAPT) Reports Q3 Loss, Lags Revenue Estimates

Rapt Therapeutics (RAPT) delivered earnings and revenue surprises of -5.00% and -33.38%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

10 months ago - Zacks Investment Research

RAPT Therapeutics Reports Third Quarter 2021 Financial Results

SOUTH SAN FRANCISCO, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and...

10 months ago - GlobeNewsWire

RAPT Therapeutics Appoints Industry Veteran Lori Lyons-Williams to its Board of Directors

SOUTH SAN FRANCISCO, Calif., Nov. 09, 2021 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and...

10 months ago - GlobeNewsWire

Rapt Therapeutics (RAPT) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Rapt Therapeutics (RAPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

10 months ago - Zacks Investment Research

RAPT Therapeutics to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and...

10 months ago - GlobeNewsWire

RAPT Therapeutics Announces Upcoming Oral Presentation of RPT193 Phase 1b Data at the 4th Inflammatory Skin Disease S...

SOUTH SAN FRANCISCO, Calif., Oct. 18, 2021 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and...

11 months ago - GlobeNewsWire

RAPT Therapeutics Announces Late-Breaking Oral Presentation of Positive Results from Phase 1b Trial of RPT193 at the ...

SOUTH SAN FRANCISCO, Calif., Sept. 30, 2021 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing an...

1 year ago - GlobeNewsWire